RxDoctor Payments Data

Syed Mahmood, MD

Pulmonary Disease · Frederick, MDNPI 1831544022

Payments from drug & device makers

$5,036in general payments, 2019–2025

Across 63 payments — averaging $79.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Pulmonx Corporation$1K
  • Olympus Corporation Of The Americas$876
  • Intuitive Surgical$815
  • Regeneron Healthcare Solutions, Inc.$137
  • E.r. Squibb & Sons, L.L.C.$131
  • plus $604 from 9 others

What the payments were for

  • Travel & lodging$3,69073%
  • Food & beverage$1,34627%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,036 in reported general payments places this provider in the 65th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$145,594
Medicare patients
507
Services billed
1,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$27,562
Spiriva RespimatTiotropium Bromide33$16,963
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$16,018
Advair HfaFluticasone Propion/Salmeterol33$12,882
XareltoRivaroxaban15$10,001
Breo ElliptaFluticasone/Vilanterol20$8,502
Incruse ElliptaUmeclidinium Bromide21$6,655
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$3,096
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,065
Albuterol Sulfate HfaAlbuterol Sulfate51$1,138
Montelukast Sodium63$1,096
Prednisone35$171
Famotidine18$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$95$42,71981 claims
Boehringer IngelheimSpiriva Respimat$87$16,96333 claims
AstraZenecaBreztri Aerosphere$59$16,01819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →